FDA Greenlights Emblaveo: A New Weapon Against Drug-Resistant Infections
08 Feb 2025
The U.S. Food and Drug Administration (FDA) has granted approval for a new treatment for complicated intra-abdominal infections (IAIs), a class of infections that affect millions of people globally every year. This new drug, Emblaveo, co-developed by pharmaceutical giants AbbVie and Pfizer, offers a promising solution for these infections, particularly...
Read More